RAB25 Antibody

What is RAB25 and why is it important in cellular research?

RAB25 is a member of the RAS oncogene family of small GTPases and belongs to the RAB11 subfamily. It plays critical roles in membrane trafficking, particularly in controlling the return of internalized membrane-associated moieties to the cell surface . RAB25's importance in research stems from its context-dependent roles in cancer biology, where it can function as either an oncogene or tumor suppressor depending on cellular context . It has been implicated in the pathogenesis of liver, breast, and ovarian cancers, among others . At the molecular level, RAB25 influences cellular bioenergetics through interaction with AKT signaling pathways, affecting glucose uptake and glycogen storage, which ultimately impacts cellular ATP levels and survival during nutrient stress .

How should I choose between monoclonal and polyclonal RAB25 antibodies?

Selection depends on your experimental goals and requirements for specificity versus sensitivity. Monoclonal antibodies like the 3F12 clone (MA5-15587, A05115) offer high specificity by recognizing a single epitope, making them excellent for applications requiring precise epitope targeting and minimal cross-reactivity . These are optimal for detecting specific conformational states of RAB25 or distinguishing it from closely related RAB family members. Polyclonal antibodies such as 13189-1-AP recognize multiple epitopes, providing stronger signal amplification and greater tolerance to protein denaturation, making them valuable for applications like Western blotting and IHC where signal strength is crucial . For novel applications or if working with challenging samples, testing both types may be necessary to determine optimal performance.

What applications are RAB25 antibodies validated for?

Commercial RAB25 antibodies have been validated for multiple applications across different experimental systems. The table below summarizes the validated applications for key commercially available antibodies:

Importantly, each antibody should be validated in your specific experimental system before proceeding with large-scale experiments .

What is the optimal antigen retrieval method for RAB25 immunohistochemistry?

For RAB25 immunohistochemistry, optimal antigen retrieval depends on the specific antibody and tissue type. For the polyclonal antibody 13189-1-AP, data indicates that TE buffer pH 9.0 is the suggested primary method, with citrate buffer pH 6.0 as an alternative . This recommendation comes from validation on human renal cell carcinoma tissue and human kidney tissue. The critical step in optimization is performing a side-by-side comparison of different antigen retrieval methods on your specific tissue type, as cellular context can significantly impact epitope accessibility. When working with tissues where RAB25 expression is expected to be contextually different (such as different cancer types), it is advisable to include positive control tissues with known RAB25 expression patterns to validate your staining protocol.

How can I verify RAB25 antibody specificity in my experimental system?

Verifying antibody specificity is crucial for RAB25 detection due to its homology with other RAB family proteins. A comprehensive validation approach should include:

• Molecular weight verification: RAB25 has a calculated molecular weight of 23 kDa, with observed weights of approximately 24 kDa . Any significant deviation may indicate cross-reactivity or post-translational modifications.

• Positive and negative controls: Use cell lines with known RAB25 expression levels. HT-29, Caco-2, and T-47D cells have been validated as positive controls for Western blotting .

• siRNA/shRNA knockdown: Compare antibody signal in cells with and without RAB25 knockdown to confirm specificity.

• Peptide competition assay: Pre-incubate the antibody with purified RAB25 protein or immunizing peptide before application to samples - specific binding should be blocked.

• Multiple antibody comparison: Use antibodies targeting different RAB25 epitopes and compare staining patterns.

• Immunoprecipitation-mass spectrometry: For ultimate validation, immunoprecipitate with the RAB25 antibody and confirm target identity via mass spectrometry.

What are the critical storage conditions for maintaining RAB25 antibody performance?

Proper storage is essential for preserving RAB25 antibody functionality. For the 13189-1-AP antibody, storage at -20°C is recommended for long-term stability, with the product remaining stable for one year after shipment. The antibody is supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3, and notably, aliquoting is specifically noted as unnecessary for -20°C storage for this product . For the A05115 monoclonal antibody, storage at -20°C is similarly recommended for long-term storage (one year), while 4°C is suitable for short-term storage and frequent use (up to one month). Repeated freeze-thaw cycles should be avoided for all antibodies as they can lead to protein denaturation and reduced performance . Small volume aliquoting is generally recommended for antibodies that will be used multiple times, though specific recommendations may vary by manufacturer.

How can I use RAB25 antibodies to investigate its context-dependent roles in cancer?

RAB25 exhibits intriguing context-dependent functions, acting as an oncogene in certain cancers while showing tumor suppressor properties in others . To investigate these dual roles, consider these methodological approaches:

• Comparative IHC analysis: Use validated RAB25 antibodies for IHC across multiple cancer types and correlate expression patterns with clinical outcomes. For example, in breast cancer, RAB25 has been reported as tumor suppressive in claudin-low subtypes but oncogenic in other contexts .

• Co-immunoprecipitation studies: Use RAB25 antibodies to isolate protein complexes and identify context-specific binding partners that may explain differential functions. Focus on AKT pathway components, as RAB25 has been shown to bind and activate AKT .

• Functional validation: Combine antibody-based detection with functional assays following RAB25 modulation. For instance, after RAB25 knockdown or overexpression, examine effects on proliferation, migration, and bioenergetics in multiple cell types representing different contexts.

• Subcellular localization analysis: Use immunofluorescence with RAB25 antibodies to determine if subcellular localization differs between contexts where RAB25 acts as an oncogene versus a tumor suppressor.

• Bioenergetic profiling: Given RAB25's role in cellular bioenergetics , combine antibody-based detection with metabolic assays to determine if glycogen accumulation and ATP maintenance differ in contexts where RAB25 has opposing functions.

How can RAB25 antibodies help investigate its role in cellular bioenergetics?

RAB25 has been identified as an unexpected regulator of cellular bioenergetics, with significant implications for cancer cell survival under stress conditions . To investigate this role:

• Co-localization studies: Use immunofluorescence with RAB25 antibodies along with markers of glycogen storage and glucose transporters to examine spatial relationships and potential functional interactions.

• Proximity ligation assays: Combine RAB25 antibodies with antibodies against AKT and other bioenergetic regulators to visualize and quantify protein-protein interactions in situ.

• Fractionation and immunoblotting: Use RAB25 antibodies for Western blotting of subcellular fractions to track RAB25 redistribution during metabolic stress and recovery.

• Chromatin immunoprecipitation (ChIP) analysis: If investigating transcriptional effects of RAB25, use RAB25 antibodies for ChIP followed by sequencing to identify genomic binding sites that might influence metabolic gene expression.

• Quantitative immunohistochemistry: Correlate RAB25 expression levels with glycogen content (through PAS staining) and markers of metabolic activity in patient samples to validate in vitro findings in a clinical context.

These approaches leverage RAB25 antibodies to provide mechanistic insights into how RAB25 mediates its effects on cellular ATP levels, glucose uptake, and glycogen storage under both normal and stress conditions .

Why might I observe differences between predicted and observed molecular weight of RAB25?

Discrepancies between predicted and observed molecular weights are common with RAB25 detection. The calculated molecular weight of RAB25 is approximately 23 kDa (213 amino acids) , but the observed molecular weight is typically around 24 kDa . This slight difference is generally considered within the normal range of experimental variation for SDS-PAGE.

• Post-translational modifications: RAB25, like other GTPases, undergoes prenylation and potentially other modifications that can alter migration patterns.

• Protein-protein interactions: Incomplete sample denaturation may result in complexes that migrate aberrantly.

• Splice variants: Alternative splicing could produce variants with different molecular weights.

• Antibody specificity issues: Cross-reactivity with related RAB family proteins (particularly other RAB11 subfamily members) might lead to bands at unexpected molecular weights.

To address this issue, compare results from multiple antibodies targeting different epitopes, and consider validating band identity through mass spectrometry or immunoprecipitation followed by Western blotting with a different RAB25 antibody.

How do I optimize RAB25 antibody dilutions for different applications?

Optimal antibody dilution varies by application, antibody, and sample type. Based on available data:

For rigorous optimization:

• Perform a dilution series (at least 3-4 dilutions within the recommended range)

• Include positive controls (HT-29, Caco-2, or T-47D cells for WB)

• For each new cell/tissue type, repeat optimization

• Document conditions systematically, including exposure times and detection methods

Remember that researchers should "titrate this reagent in each testing system to obtain optimal results" .

How can RAB25 antibodies be used alongside novel inhibitors in therapeutic development?

The development of stapled peptide inhibitors of RAB25, such as RFP14, opens new research directions where antibodies play a crucial role in target validation and efficacy assessment . Methodological approaches include:

• Target engagement studies: Use RAB25 antibodies in cell-based assays to confirm that inhibitors reach and interact with RAB25 in relevant cellular compartments.

• Phenotypic profiling: Combine RAB25 inhibition (via stapled peptides) with antibody-based detection to correlate inhibitor efficacy with RAB25 expression levels and localization patterns.

• Mechanistic investigations: Use RAB25 antibodies to study how inhibitors affect RAB25's interactions with binding partners, particularly FIP-family proteins, through co-immunoprecipitation and proximity ligation assays .

• Biomarker development: Apply RAB25 antibodies in analyzing patient samples to identify predictive biomarkers of response to RAB25-targeted therapies, focusing on the context-specific nature of RAB25 function.

• Resistance mechanisms: In cells developing resistance to RAB25 inhibitors, use antibody-based approaches to investigate alterations in RAB25 expression, localization, or binding partners.

This integration of antibody-based techniques with novel inhibitor research helps bridge the gap between target validation and therapeutic development, particularly important given RAB25's context-dependent roles in cancer .

What approaches can help resolve contradictory RAB25 expression data in different cancer contexts?

The dual nature of RAB25 as both oncogene and tumor suppressor creates challenges in interpreting experimental data . To address contradictory findings:

• Standardized antibody validation: Use rigorously validated antibodies with demonstrated specificity for RAB25, and standardize detection protocols across studies.

• Context documentation: Thoroughly document cellular context, including tissue origin, differentiation state, and genetic background, as these factors appear to determine RAB25 function.

• Multi-level analysis: Combine protein detection (using antibodies) with mRNA analysis to distinguish between transcriptional and post-transcriptional regulation.

• Single-cell approaches: Apply RAB25 antibodies in single-cell imaging or flow cytometry to identify cell subpopulations with different RAB25 expression patterns within heterogeneous samples.

• Network analysis: Use RAB25 antibodies alongside antibodies for interacting partners and downstream effectors to build context-specific protein interaction networks.

• Integration with genomic data: Correlate RAB25 protein expression with genomic alterations and transcriptomic profiles to identify molecular contexts associated with oncogenic versus tumor suppressive functions.

These approaches, centered on careful antibody-based detection, help reconcile apparently contradictory roles of RAB25 across different cancer types and experimental systems .